BofA downgraded Harmony Biosciences to Underperform from Neutral with an unchanged price target of $30. The analyst cites a lack of “high-impact catalysts” and the company’s challenging path to addressing a 2029 Wakix loss of exclusivity for the downgrade. Harmony is a single-product biotech company selling Wakix for the treatment of narcoleps, says the firm, which believes regulatory exclusivities will only extend another five years to 2029.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HRMY: